FDA approves J&J combination therapy to treat a type of lung cancer

A US health regulator has approved Johnson & Johnson’s Uterapia in combination with other chemotherapy drugs for the first-line treatment of lung cancer. The FDA has approved J&J’s Rybrevant combination therapy with carboplatin and pemetrexed for patients with non-small cell lung cancer.

Share This Post:

POPULAR POSTS
FOLLOW US
Like Us On Facebook
Follow Us On Twitter
Subscribe To Our Channel
TikTok
LIVE STREAM